[{"id":"3b32d8a5-c5ea-4195-a505-ea0c6246c9c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119024","created_at":"2021-01-18T20:07:53.813Z","updated_at":"2025-02-25T12:27:21.879Z","phase":"Phase 1","brief_title":"Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","source_id_and_acronym":"NCT04119024","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-24"},{"id":"39be432b-e1d2-4ded-8099-18c4960548fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06805825","created_at":"2025-02-25T15:15:39.171Z","updated_at":"2025-02-25T15:15:39.171Z","phase":"Phase 1","brief_title":"A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit","source_id_and_acronym":"NCT06805825","lead_sponsor":"Novelty Nobility, Inc.","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NN3201"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 02/03/2025","start_date":" 02/03/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-13"},{"id":"c388e765-68a9-4c36-8000-4ede187305c8","acronym":"CA224-094","url":"https://clinicaltrials.gov/study/NCT04552223","created_at":"2021-01-18T21:45:58.107Z","updated_at":"2025-02-25T14:29:34.845Z","phase":"Phase 2","brief_title":"Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma","source_id_and_acronym":"NCT04552223 - CA224-094","lead_sponsor":"Jose Lutzky, MD","biomarkers":" LAG3 • CTLA4","pipe":"","alterations":" ","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2026","study_completion_date":" 01/04/2026","last_update_posted":"2025-02-13"},{"id":"8faa9c2f-7698-40c3-8644-3401597d3da2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05628883","created_at":"2022-11-29T15:57:45.457Z","updated_at":"2025-02-25T16:33:12.261Z","phase":"Phase 1","brief_title":"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma","source_id_and_acronym":"NCT05628883","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF • IL2","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TIDAL-01"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/22/2022","start_date":" 11/22/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-07"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"c40fa03c-9c20-4928-9562-c4d2f144ca96","acronym":"DAR-UM-2","url":"https://clinicaltrials.gov/study/NCT05987332","created_at":"2023-08-14T15:10:06.767Z","updated_at":"2025-02-25T16:27:34.251Z","phase":"Phase 2/3","brief_title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","source_id_and_acronym":"NCT05987332 - DAR-UM-2","lead_sponsor":"IDEAYA Biosciences","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Xalkori (crizotinib) • Yervoy (ipilimumab) • dacarbazine • darovasertib (IDE196)"],"overall_status":"Recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 01/15/2028","study_completion_date":" 01/15/2028","last_update_posted":"2025-02-04"},{"id":"65eed3dd-6e61-408e-98c2-7b567021d3e7","acronym":"KEYNOTE-G05","url":"https://clinicaltrials.gov/study/NCT06784648","created_at":"2025-02-25T16:11:37.790Z","updated_at":"2025-02-25T16:11:37.790Z","phase":"Phase 1/2","brief_title":"Different Doses of BI-1607 in Combination with Pembrolizumab and Ipilimumab, in Participants with Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT06784648 - KEYNOTE-G05","lead_sponsor":"BioInvent International AB","biomarkers":" PD-1 • FCGR2A","pipe":"","alterations":" ","tags":["PD-1 • FCGR2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • BI-1607"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 12/11/2024","start_date":" 12/11/2024","primary_txt":" Primary completion: 09/30/2028","primary_completion_date":" 09/30/2028","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2025-01-20"},{"id":"49dce72b-9d7c-4760-9f04-db0fc8e432e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06070012","created_at":"2023-10-06T14:11:25.919Z","updated_at":"2025-02-25T16:27:38.972Z","phase":"Phase 2","brief_title":"Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma","source_id_and_acronym":"NCT06070012","lead_sponsor":"Diwakar Davar","biomarkers":" LAG3 • CTLA4","pipe":" | ","alterations":" HLA-A*02:01","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kimmtrak (tebentafusp-tebn)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 01/31/2025","start_date":" 01/31/2025","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2029","study_completion_date":" 11/30/2029","last_update_posted":"2025-01-06"},{"id":"9795b4cb-6f73-4ce5-a9a8-6ba8acc8d386","acronym":"Keynote MK-3475-B66","url":"https://clinicaltrials.gov/study/NCT03611868","created_at":"2021-01-18T17:45:12.835Z","updated_at":"2025-02-25T16:08:10.551Z","phase":"Phase 1/2","brief_title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","source_id_and_acronym":"NCT03611868 - Keynote MK-3475-B66","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" ATM mutation • TP53 wild-type","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 08/29/2018","start_date":" 08/29/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2024-07-19"},{"id":"f270357c-b837-458a-950f-910b0ee31575","acronym":"","url":"https://clinicaltrials.gov/study/NCT01587352","created_at":"2023-11-26T19:51:41.019Z","updated_at":"2024-07-02T16:35:00.381Z","phase":"Phase 2","brief_title":"Vorinostat in Treating Patients With Metastatic Melanoma of the Eye","source_id_and_acronym":"NCT01587352","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GNAQ • BAP1 • GNA11","pipe":"","alterations":" ","tags":["GNAQ • BAP1 • GNA11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zolinza (vorinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/29/2012","start_date":" 05/29/2012","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-29"},{"id":"711124ce-0659-42bd-8b65-60940e5975b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05415072","created_at":"2022-06-10T12:58:54.272Z","updated_at":"2024-07-02T16:35:07.121Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","source_id_and_acronym":"NCT05415072","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" GNAQ","pipe":"","alterations":" ","tags":["GNAQ"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DYP688"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-04-29"},{"id":"38d6c31c-a42e-4154-b3f7-edcf460d915e","acronym":"NCI-2018-01211","url":"https://clinicaltrials.gov/study/NCT03025256","created_at":"2021-01-18T14:53:25.115Z","updated_at":"2024-07-02T16:35:10.137Z","phase":"Phase 1","brief_title":"Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease","source_id_and_acronym":"NCT03025256 - NCI-2018-01211","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • IL2","pipe":"","alterations":" ","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/02/2018","start_date":" 05/02/2018","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-04-11"},{"id":"e6a761ac-dd0a-4052-9115-9278013bbd57","acronym":"","url":"https://clinicaltrials.gov/study/NCT02519322","created_at":"2021-01-18T12:10:30.425Z","updated_at":"2025-02-25T16:30:41.228Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Checkpoint Blockade","source_id_and_acronym":"NCT02519322","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 02/02/2016","start_date":" 02/02/2016","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 01/26/2023","study_completion_date":" 01/26/2023","last_update_posted":"2024-04-05"},{"id":"04df3049-aecf-4362-a49a-2285288f64a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05075993","created_at":"2021-10-13T16:58:12.200Z","updated_at":"2024-07-02T16:35:11.360Z","phase":"Phase 1","brief_title":"Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors","source_id_and_acronym":"NCT05075993","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • cyclophosphamide intravenous • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)"],"overall_status":"Recruiting","enrollment":" Enrollment 352","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 02/02/2027","primary_completion_date":" 02/02/2027","study_txt":" Completion: 02/02/2027","study_completion_date":" 02/02/2027","last_update_posted":"2024-04-04"},{"id":"e4e5b5ae-4209-402e-817d-04b5df309c96","acronym":"ON-5001","url":"https://clinicaltrials.gov/study/NCT06022029","created_at":"2023-09-01T17:11:43.841Z","updated_at":"2024-07-02T16:35:12.473Z","phase":"Phase 1","brief_title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","source_id_and_acronym":"NCT06022029 - ON-5001","lead_sponsor":"OncoNano Medicine, Inc.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • ONM-501"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 10/13/2023","start_date":" 10/13/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 08/29/2026","study_completion_date":" 08/29/2026","last_update_posted":"2024-03-28"},{"id":"82abbfb4-9687-48c6-8688-0f55469253e1","acronym":"DUET-3","url":"https://clinicaltrials.gov/study/NCT03752398","created_at":"2021-01-18T18:26:08.585Z","updated_at":"2024-07-02T16:35:19.743Z","phase":"Phase 1","brief_title":"A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)","source_id_and_acronym":"NCT03752398 - DUET-3","lead_sponsor":"Xencor, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • izuralimab (XmAb23104)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-02-12"},{"id":"7ff4baf4-9627-40b5-906f-346088349ad5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03068624","created_at":"2021-01-18T15:07:02.967Z","updated_at":"2024-07-02T16:35:22.311Z","phase":"Phase 1","brief_title":"Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma","source_id_and_acronym":"NCT03068624","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • cyclophosphamide • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/08/2017","start_date":" 09/08/2017","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-01-25"},{"id":"568b36cb-3adb-4ca4-b782-7807a06c9148","acronym":"","url":"https://clinicaltrials.gov/study/NCT05482074","created_at":"2022-08-01T14:54:37.467Z","updated_at":"2025-02-25T15:00:33.008Z","phase":"Phase 2","brief_title":"Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2","source_id_and_acronym":"NCT05482074","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA1 mutation • BRCA2 deletion • BRCA1 deletion","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • BRCA2 deletion • BRCA1 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/04/2022","start_date":" 10/04/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-01-19"},{"id":"4d03b67b-68b2-483a-a512-97aaeedafd94","acronym":"","url":"https://clinicaltrials.gov/study/NCT03865212","created_at":"2021-01-18T19:03:32.995Z","updated_at":"2024-07-02T16:35:24.120Z","phase":"Phase 1","brief_title":"Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT03865212","lead_sponsor":"Mayo Clinic","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VSV-IFNbetaTYRP1 • Voyager-V1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/12/2019","start_date":" 06/12/2019","primary_txt":" Primary completion: 01/20/2027","primary_completion_date":" 01/20/2027","study_txt":" Completion: 01/20/2027","study_completion_date":" 01/20/2027","last_update_posted":"2024-01-09"},{"id":"af094930-141f-44cb-99b2-08d2ebb813d2","acronym":"AMUM","url":"https://clinicaltrials.gov/study/NCT05502900","created_at":"2022-08-16T11:56:19.168Z","updated_at":"2024-07-02T16:35:28.240Z","phase":"Phase 3","brief_title":"Adjuvant Melatonin for Uveal Melanoma","source_id_and_acronym":"NCT05502900 - AMUM","lead_sponsor":"Gustav Stalhammar","biomarkers":" BAP1","pipe":"","alterations":" ","tags":["BAP1"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/02/2022","start_date":" 10/02/2022","primary_txt":" Primary completion: 01/01/2031","primary_completion_date":" 01/01/2031","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2023-11-22"},{"id":"ea1db548-3290-43ce-90b8-d7da0c14c574","acronym":"TIMAR1","url":"https://clinicaltrials.gov/study/NCT04904120","created_at":"2022-05-11T22:55:53.385Z","updated_at":"2024-07-02T16:35:30.189Z","phase":"Phase 1","brief_title":"Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy","source_id_and_acronym":"NCT04904120 - TIMAR1","lead_sponsor":"Viewpoint Molecular Targeting","biomarkers":" MC1R","pipe":"","alterations":" ","tags":["MC1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMT-01"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 03/05/2021","start_date":" 03/05/2021","primary_txt":" Primary completion: 09/20/2022","primary_completion_date":" 09/20/2022","study_txt":" Completion: 09/20/2022","study_completion_date":" 09/20/2022","last_update_posted":"2023-11-07"},{"id":"a3b94b21-6e56-4be0-94d8-6e762635e9e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04792463","created_at":"2021-03-11T13:52:41.075Z","updated_at":"2024-07-02T16:35:31.698Z","phase":"","brief_title":"Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome","source_id_and_acronym":"NCT04792463","lead_sponsor":"Mohamed Abdel-Rahman","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/03/2015","start_date":" 03/03/2015","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-10-25"},{"id":"12fc1d17-0a06-4691-bf0b-18767b9a6e88","acronym":"Mel66","url":"https://clinicaltrials.gov/study/NCT04364230","created_at":"2021-01-18T21:05:35.842Z","updated_at":"2024-07-02T16:35:33.934Z","phase":"Phase 1/2","brief_title":"Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)","source_id_and_acronym":"NCT04364230 - Mel66","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" BRAF • CD4 • FOXP3","pipe":"","alterations":" ","tags":["BRAF • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-1140 • Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/28/2020","start_date":" 09/28/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-10-11"},{"id":"94c45794-3c7a-4a80-9968-91c364190829","acronym":"","url":"https://clinicaltrials.gov/study/NCT03207347","created_at":"2021-01-18T15:48:36.731Z","updated_at":"2025-02-25T13:12:22.396Z","phase":"Phase 2","brief_title":"A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)","source_id_and_acronym":"NCT03207347","lead_sponsor":"University of Florida","biomarkers":" PTEN • IDH1 • IDH2 • ARID1A • BAP1 • CDK4 • CHEK2 • RAD51 • BRIP1 • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • CDK2 • WRN • RAD52 • BACH1 • FANCG • PRKDC • RPA1 • ABRAXAS1 • FEN1 • SLX4","pipe":" | ","alterations":" BARD1 mutation","tags":["PTEN • IDH1 • IDH2 • ARID1A • BAP1 • CDK4 • CHEK2 • RAD51 • BRIP1 • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • CDK2 • WRN • RAD52 • BACH1 • FANCG • PRKDC • RPA1 • ABRAXAS1 • FEN1 • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 08/30/2022","study_completion_date":" 08/30/2022","last_update_posted":"2023-09-15"}]